[PDF][PDF] Paediatric rheumatology Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases
I Oomen, ANS Rashid, AHM Bouts… - Clinical and …, 2022 - researchgate.net
Objective Rituximab (RTX) is a chimeric monoclonal CD20-antibody. Lack of efficacy has
been suggested to be related to the presence of anti-drug antibodies (ADA). The aims of this …
been suggested to be related to the presence of anti-drug antibodies (ADA). The aims of this …
Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases.
I Oomen, AHM Bouts, SC Gouw… - Clinical and …, 2021 - europepmc.org
Objectives Rituximab (RTX) is a chimeric monoclonal CD20-antibody. Lack of efficacy has
been suggested to be related to the presence of anti-drug antibodies (ADA). The aims of this …
been suggested to be related to the presence of anti-drug antibodies (ADA). The aims of this …
Safety of rituximab in children with auto-immune diseases
B Bader-Meunier, P Quartier, C Wouters - Pediatric Rheumatology, 2008 - Springer
Safety of rituximab in children with auto-immune diseases | Pediatric Rheumatology Skip to main
content SpringerLink Account Menu Find a journal Publish with us Track your research Search …
content SpringerLink Account Menu Find a journal Publish with us Track your research Search …
Pharmacodynamics of rituximab in paediatric immune mediated diseases: B cell depletion and repopulation, effects on immunoglobulin levels and risk for infections
ANS Rashid, SC Bergkamp… - Clinical and …, 2023 - pubmed.ncbi.nlm.nih.gov
Objectives Rituximab (RTX), used for treatment in paediatric immune-mediated diseases,
can lead to hypogammaglobulinaemia and thus to an increased risk of infection, but data on …
can lead to hypogammaglobulinaemia and thus to an increased risk of infection, but data on …
[PDF][PDF] Paediatric rheumatology Pharmacodynamics of rituximab in paediatric immune mediated diseases: B cell depletion and repopulation, effects on …
ANS Rashid, SC Bergkamp… - Clinical and …, 2023 - clinexprheumatol.org
Objective Rituximab (RTX), used for treatment in paediatric immune-mediated diseases, can
lead to hypogammaglobulinaemia and thus to an increased risk of infection, but data on …
lead to hypogammaglobulinaemia and thus to an increased risk of infection, but data on …
Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases
Aims Rituximab is a chimeric IgG‐1 monoclonal antibody that depletes B cells, aiding in the
treatment of several conditions including autoimmune diseases. It is not licensed for use in …
treatment of several conditions including autoimmune diseases. It is not licensed for use in …
Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients
B Lioger, SR Edupuganti, D Mulleman… - British Journal of …, 2017 - Wiley Online Library
Aims Rituximab is a monoclonal antibody directed against CD20, which is approved in
rheumatoid arthritis (RA). This study aimed at assessing the influence of CD19+ cell counts …
rheumatoid arthritis (RA). This study aimed at assessing the influence of CD19+ cell counts …
Evaluation of pediatric rheumatologists' approach to rituximab use: a questionnaire study
ENS Yayla, DG Yıldırım, HA Dündar… - European journal of … - pubmed.ncbi.nlm.nih.gov
Rituximab (RTX) is a chimeric monoclonal antibody that targets the CD20 antigen on B cells
and is used in various autoimmune disorders. In this study, we aimed to measure the …
and is used in various autoimmune disorders. In this study, we aimed to measure the …
Evaluation of pediatric rheumatologists' approach to rituximab use: a questionnaire study
EN Sunar Yayla, D Gezgin Yıldırım… - European Journal of …, 2024 - Springer
Rituximab (RTX) is a chimeric monoclonal antibody that targets the CD20 antigen on B cells
and is used in various autoimmune disorders. In this study, we aimed to measure the …
and is used in various autoimmune disorders. In this study, we aimed to measure the …
G261 Prescribing practices of rituximab in children: a 5-year retrospective review
Aims Rituximab, an anti-lymphocyte monoclonal antibody, is not currently licensed for use in
children but is used for treatment of a variety of conditions. The purpose of this study was to …
children but is used for treatment of a variety of conditions. The purpose of this study was to …
相关搜索
- pharmacokinetics and pharmacodynamics rituximab in children
- pharmacodynamics of rituximab autoimmune diseases
- pharmacodynamics of rituximab paediatric patients
- pharmacodynamics of rituximab risk for infections
- pharmacodynamics of rituximab immunoglobulin levels
- pharmacodynamics of rituximab cell depletion
- rheumatic diseases rituximab therapy
- rituximab pharmacokinetics arthritis patients
- paediatric patients autoimmune diseases